Although the era of biologic treatment modalities has not led to any approvals for pSS, the arrival of JAK inhibitors in RA (tofacitinib and baricitinib), with additional compounds at late stage or close to approval (upadacitinib and filgotinib), suggests that the potential of these JAK inhibitors to target IFN pathways (at least partially type I and II IFN) is of particular interest in pSS [41]. Here, SGCG is linked to rheumatoid arthritis.